<p>想投资一些价格低廉且长期潜力巨大的股票吗？以下列出的股票可能是寻求便宜货的投资者的绝佳选择，因为每只股票的交易价格都低于每股 100 美元，并且被严重低估。尽管它们最近的表现并不理想，但从长远来看，考虑到其低估值，它们可能会带来可观的回报。</p>
<p>以下是您为何要考虑投资 <strong>诺和诺德公司</strong>(NVO -4.54%)、<strong>塔吉特</strong>(TGT -1.32%) 和 <strong>辉瑞</strong>(PFE -1.97%) 的原因，尽管它们今年的表现平平。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzQxMTAvc29tZW9uZS1yZXZpZXdpbmctYS1zdG9jay1vbi10aGVpci1jb21wdXRlci5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzQxMTAvc29tZW9uZS1yZXZpZXdpbmctYS1zdG9jay1vbi10aGVpci1jb21wdXRlci5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. 诺和诺德公司</h2>
<p>丹麦制药公司诺和诺德在 GLP-1 药物市场中占据重要地位，Wegovy（用于减肥）和 Ozempic（用于糖尿病）是其两款核心产品，为其业务带来了数十亿美元的收入。</p>
<p>由于公司下调了财政年度的业绩指引，导致增长速度低于预期，其股价在 7 月底暴跌。诺和诺德一直在努力阻止其热门药物的仿制版本进入市场，这两大挑战导致其股价今年迄今已下跌近 32%；截至周三收盘，股价仅略低于 59 美元。</p>
<p>尽管股价看起来不太乐观，但仍有很多理由对其保持乐观。Wegovy 仍处于增长的早期阶段，特别是在其扩展到新市场时。同时，Wegovy 的口服版本看起来前景可期，参与三期临床试验的参与者在 64 周后平均减重 16.6%，与注射版本的表现相符。</p>
<p>这只医疗股票的市盈率（P/E）仅为 15，考虑到其长期增长潜力，这看起来是个极具吸引力的交易。尽管今年表现不佳，诺和诺德有望反弹。</p>
<h2>2. 塔吉特</h2>
<p>大型零售商塔吉特是另一只今年表现不佳的股票。其股价下跌近 35%，目前交易价格约为每股 88 美元。今年前六个月的收入总计为 491 亿美元，同比下降 2%。消费者在可自由支配支出上有所收缩，这使得公司难以实现收入增长。</p>
<p>这对塔吉特来说是个挑战：经济状况不会迅速好转，尤其是在消费者面临因关税而上涨的成本时。然而，今年早些时候，公司宣布计划到本世纪末将销售额增加 150 亿美元，专注于其在线市场并提供当日送达服务。</p>
<p>未来面临挑战，但该业务并非岌岌可危。过去 12 个月内，它产生了近 30 亿美元的自由现金流，财务状况良好。其市盈率略高于 10，估值极低。您需要对塔吉特保持耐心，但这似乎是一只被低估的值得购买的股票。</p>
<h2>3. 辉瑞</h2>
<p>本名单的最后一位是另一家顶级医疗公司：辉瑞。截至周三收盘，股价略高于 24 美元，似乎又面临一个艰难的年度——自 1 月以来下跌了 9%。与 2021 年其 COVID-19 疫苗和治疗产品的高峰相比，股价已下跌超过 50%。</p>
<p>增长型投资者对公司的未来感到担忧，因为它面临多个专利悬崖，当前的销售情况也并不强劲。到 2025 年上半年，收入仅增长了 1%，达到 284 亿美元。</p>
<p>但辉瑞通过收购不断扩展其产品线，并最近宣布计划以高达 73 亿美元收购 GLP-1 药物制造商 <strong>Metsera</strong>。在 GLP-1 产品方面未能取得成功后，辉瑞希望此次收购能为其在肥胖市场提供强有力的选择。然而，没有任何保证：Metsera 尚未产生任何收入，尽管它有一些前景可期的药物在开发中，但迄今为止没有任何药物获得批准。</p>
<p>辉瑞强劲的财务状况是投资者不应放弃该股票的原因。尽管增长可能缓慢，但它产生了充足的自由现金流（过去 12 个月为 124 亿美元），可以用来帮助追求如 Metsera 及其他公司的收购。并非每一次举措都会成功，但只需一款有潜力的重磅药物，就能增强其收入并吸引增长型投资者。</p>
<p>与本名单上的其他股票一样，辉瑞也存在一定风险。但以 13 的市盈率来看，它是一项便宜的投资，具有良好的安全边际，可以补偿投资者的不确定性。</p>

诺和诺德公司

塔吉特

<p>本文强调了三只被低估的股票，价格均在 100 美元以下：诺和诺德公司、塔吉特和辉瑞。尽管诺和诺德公司今年下跌了 32%，但在 GLP-1 药物市场中显示出长期增长潜力。塔吉特下跌了 35%，计划通过专注于在线增长来增加 150 亿美元的销售额，当前市盈率低于 10。辉瑞的股价超过 24 美元，面临挑战，但财务状况强劲，并通过收购（包括 Metsera）扩展其产品线。尽管当前面临困难，每只股票都为寻求长期收益的投资者提供了买入机会</p>

<p>Want to invest in some low-priced stocks that possess a lot of upside in the long run? The stocks listed below could be great options for bargain hunters, as each one trades at less than $100 per share and is deeply undervalued. While they haven't been doing all that well of late, over the long run, they could generate some terrific returns given their low valuations.</p>
<div class="lb-trans"><p>想投资一些价格低廉且长期潜力巨大的股票吗？以下列出的股票可能是寻求便宜货的投资者的绝佳选择，因为每只股票的交易价格都低于每股 100 美元，并且被严重低估。尽管它们最近的表现并不理想，但从长远来看，考虑到其低估值，它们可能会带来可观的回报。</p>
</div><p>Here's why you'll want to consider putting $100 (or more) toward investments in <strong>Novo Nordisk</strong>(NVO -4.54%), <strong>Target</strong>(TGT -1.32%), and <strong>Pfizer</strong>(PFE -1.97%) despite their lackluster performances this year.</p>
<div class="lb-trans"><p>以下是您为何要考虑投资 <strong>诺和诺德公司</strong>(NVO -4.54%)、<strong>塔吉特</strong>(TGT -1.32%) 和 <strong>辉瑞</strong>(PFE -1.97%) 的原因，尽管它们今年的表现平平。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzQxMTAvc29tZW9uZS1yZXZpZXdpbmctYS1zdG9jay1vbi10aGVpci1jb21wdXRlci5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F834110%2Fsomeone-reviewing-a-stock-on-their-computer.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. Novo Nordisk</h2>
<div class="lb-trans"><h2>1. 诺和诺德公司</h2>
</div><p>Danish pharma company Novo Nordisk is a big player in the GLP-1 drug market, with Wegovy (for weight loss) and Ozempic (for diabetes) being two core products that generate billions of dollars in revenue for its business.</p>
<div class="lb-trans"><p>丹麦制药公司诺和诺德在 GLP-1 药物市场中占据重要地位，Wegovy（用于减肥）和 Ozempic（用于糖尿病）是其两款核心产品，为其业务带来了数十亿美元的收入。</p>
</div><p>Its share price crashed in late July when the company lowered its guidance for the fiscal year, as growth was a bit slower than expected. Novo Nordisk has been fighting a losing battle to keep knockoff compounded versions of its popular drugs off the market. These two headwinds have resulted in the stock price falling close to 32% so far this year; as of Wednesday's close, shares were trading at just under $59.</p>
<div class="lb-trans"><p>由于公司下调了财政年度的业绩指引，导致增长速度低于预期，其股价在 7 月底暴跌。诺和诺德一直在努力阻止其热门药物的仿制版本进入市场，这两大挑战导致其股价今年迄今已下跌近 32%；截至周三收盘，股价仅略低于 59 美元。</p>
</div><p>While the stock looks like it's in bad shape, there's plenty of reason to remain bullish on it. Wegovy is still in the early stages of its growth, particularly as it expands into new markets. Meanwhile, the oral version of Wegovy looks promising, with participants in a phase 3 trial losing an average of 16.6% of their body weight after 64 weeks, which is in line with how the injectable version performs.</p>
<div class="lb-trans"><p>尽管股价看起来不太乐观，但仍有很多理由对其保持乐观。Wegovy 仍处于增长的早期阶段，特别是在其扩展到新市场时。同时，Wegovy 的口服版本看起来前景可期，参与三期临床试验的参与者在 64 周后平均减重 16.6%，与注射版本的表现相符。</p>
</div><p>The healthcare stock trades at a price-to-earnings (P/E) multiple of only 15, which makes it look like a steal of a deal given its long-term growth potential. While it's not having a great year, Novo Nordisk is likely to rebound.</p>
<div class="lb-trans"><p>这只医疗股票的市盈率（P/E）仅为 15，考虑到其长期增长潜力，这看起来是个极具吸引力的交易。尽管今年表现不佳，诺和诺德有望反弹。</p>
</div><h2>2. Target</h2>
<div class="lb-trans"><h2>2. 塔吉特</h2>
</div><p>Big-box retailer Target is another stock that has been struggling badly this year. It's down almost 35%, and is currently trading at around $88 per share. Its revenue through the first six months of the year has totaled $49.1 billion, down 2% year over year. Consumers have been pulling back on discretionary spending, and that's made it difficult for the company to grow its top line.</p>
<div class="lb-trans"><p>大型零售商塔吉特是另一只今年表现不佳的股票。其股价下跌近 35%，目前交易价格约为每股 88 美元。今年前六个月的收入总计为 491 亿美元，同比下降 2%。消费者在可自由支配支出上有所收缩，这使得公司难以实现收入增长。</p>
</div><p>It's a challenge for Target: Economic conditions won't make a quick turnaround easy, particularly as consumers battle higher costs due to tariffs. Earlier this year, however, the company announced plans to grow sales by $15 billion by the end of the decade, as it focuses on its online marketplace and offering same-day delivery.</p>
<div class="lb-trans"><p>这对塔吉特来说是个挑战：经济状况不会迅速好转，尤其是在消费者面临因关税而上涨的成本时。然而，今年早些时候，公司宣布计划到本世纪末将销售额增加 150 亿美元，专注于其在线市场并提供当日送达服务。</p>
</div><p>There are challenges ahead, but the business is by no means in peril. It generated nearly $3 billion in free cash flow over the trailing 12 months and is in solid financial shape. It trades at an incredibly low valuation, with its P/E multiple slightly over 10. You'll need some patience with Target, but this seems like an underrated stock worth buying.</p>
<div class="lb-trans"><p>未来面临挑战，但该业务并非岌岌可危。过去 12 个月内，它产生了近 30 亿美元的自由现金流，财务状况良好。其市盈率略高于 10，估值极低。您需要对塔吉特保持耐心，但这似乎是一只被低估的值得购买的股票。</p>
</div><h2>3. Pfizer</h2>
<div class="lb-trans"><h2>3. 辉瑞</h2>
</div><p>Rounding out this list is another top healthcare company: Pfizer. As of Wednesday's close, the stock was trading at just over $24, and seems on track for another challenging year -- it's down 9% since January. It's also down more than 50% from the highs it reached back in 2021, when its COVID-19 vaccine and treatment were promising products in its portfolio.</p>
<div class="lb-trans"><p>本名单的最后一位是另一家顶级医疗公司：辉瑞。截至周三收盘，股价略高于 24 美元，似乎又面临一个艰难的年度——自 1 月以来下跌了 9%。与 2021 年其 COVID-19 疫苗和治疗产品的高峰相比，股价已下跌超过 50%。</p>
</div><p>Growth investors are concerned about the company's future, as it faces multiple patent cliffs, and its sales today aren't all that strong. Through the first half of 2025, revenue has risen by just 1%, to $28.4 billion.</p>
<div class="lb-trans"><p>增长型投资者对公司的未来感到担忧，因为它面临多个专利悬崖，当前的销售情况也并不强劲。到 2025 年上半年，收入仅增长了 1%，达到 284 亿美元。</p>
</div><p>But Pfizer has been expanding its pipeline via acquisitions, and recently announced plans to purchase GLP-1 drugmaker <strong>Metsera</strong> for up to $7.3 billion. After falling short with its GLP-1 products, Pfizer is hoping the acquisition can give it some formidable options in the obesity market. There are no guarantees, however: Metsera isn't generating any revenue yet, and while it has some promising drugs in development, nothing has been approved thus far.</p>
<div class="lb-trans"><p>但辉瑞通过收购不断扩展其产品线，并最近宣布计划以高达 73 亿美元收购 GLP-1 药物制造商 <strong>Metsera</strong>。在 GLP-1 产品方面未能取得成功后，辉瑞希望此次收购能为其在肥胖市场提供强有力的选择。然而，没有任何保证：Metsera 尚未产生任何收入，尽管它有一些前景可期的药物在开发中，但迄今为止没有任何药物获得批准。</p>
</div><p>Pfizer's strong financials are why investors shouldn't give up on the stock. While growth may be sluggish, it generates ample free cash flow ($12.4 billion over the past 12 months), which it can use to help pursue acquisitions such as Metsera and other companies. Not every move will pay off, but all it needs is just one big blockbuster drug that shows promise, which can strengthen its top line and attract growth investors in the process.</p>
<div class="lb-trans"><p>辉瑞强劲的财务状况是投资者不应放弃该股票的原因。尽管增长可能缓慢，但它产生了充足的自由现金流（过去 12 个月为 124 亿美元），可以用来帮助追求如 Metsera 及其他公司的收购。并非每一次举措都会成功，但只需一款有潜力的重磅药物，就能增强其收入并吸引增长型投资者。</p>
</div><p>As with the other stocks on this list, there's some risk with Pfizer. But at a P/E of 13, it's a cheap buy that comes with a good margin of safety, which can compensate investors for the uncertainty.</p>
<div class="lb-trans"><p>与本名单上的其他股票一样，辉瑞也存在一定风险。但以 13 的市盈率来看，它是一项便宜的投资，具有良好的安全边际，可以补偿投资者的不确定性。</p>
</div>

3 只极其便宜的股票，你现在可以以不到 100 美元的价格购买